These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

944 related items for PubMed ID: 16720636

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P, Landt O, Serre G, Roudier J, Roudier C.
    Arthritis Rheum; 2007 Dec 15; 57(8):1426-30. PubMed ID: 18050183
    [Abstract] [Full Text] [Related]

  • 4. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D.
    Arthritis Rheum; 2003 Jul 15; 48(7):1849-52. PubMed ID: 12847678
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct 15; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.
    Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts AM, Scheffer H, Radstake TR, Creemers MC, de Rooij DJ, van Riel PL, Franke B, Barrera P.
    Ann Rheum Dis; 2008 Aug 15; 67(8):1174-7. PubMed ID: 18385279
    [Abstract] [Full Text] [Related]

  • 16. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.
    J Rheumatol; 2011 Nov 15; 38(11):2346-54. PubMed ID: 21965648
    [Abstract] [Full Text] [Related]

  • 17. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun 15; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML.
    Dan Med Bull; 2011 Nov 15; 58(11):B4320. PubMed ID: 22047935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.